Nurix Q1 2023 Earnings Report

Nurix Therapeutics reported first quarter fiscal year 2023 financial results and provided a corporate update.

Key Takeaways

Nurix Therapeutics reported collaboration revenue of $12.7 million for the first quarter ended February 28, 2023. The company's net loss was $40.7 million, or ($0.75) per share. Cash, cash equivalents and marketable securities totaled $325.6 million as of February 28, 2023.

Gilead licensed NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment.

Expanded therapeutic area potential of protein degradation pipeline with Gilead in rheumatoid arthritis and other inflammatory diseases.

Achieved an additional $7.5 million in research milestones in collaborations with Gilead and Sanofi.

Maintained strong financial position with cash and marketable securities of $325.6 million as of February 28, 2023.

Total Revenue

$12.7M

Previous year: $9.62M

+31.8%

EPS

-$0.75

Previous year: -$0.95

-21.1%